All In Biotech

Drug Trial Radar · NCT00717457

A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

Randomized, Active Controlled, Open Label Study to Compare Taspoglutide vs Exenatide as add-on Treatment to Metformin and/or Thiazolidinediones in Patients With Type 2 Diabetes Mellitus

Last checked: Nov 20, 2026Latest source record: Nov 2, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,189 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,189

Actual

Start

Jul 2008

Primary completion

Mar 2011

Study completion Mar 2011

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jul 17, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This 3-arm study will assess the efficacy, safety and tolerability of taspoglutide compared with exenatide in patients with type 2 diabetes mellitus inadequately controlled with metformin, thiazolidinedione or a combination of both. Patients will be randomized to receive taspoglutide (10mg once weekly or 10mg once weekly for 4 weeks followed by 20mg once weekly) or exenatide (5 micrograms twice daily for 4 weeks followed by 10 micrograms twice daily) in a ratio of 1:1:1 in addition to continued prestudy metformin and thiazolidinedione either alone or in combination. The anticipated time on study treatment is 3+ years, and the target sample size is \>500 individuals.

Conditions

  • Diabetes Mellitus Type 2

Interventions

  • exenatideDrug

    5mg twice daily for 4 weeks followed by 10mg twice daily

  • taspoglutideDrug

    10mg once weekly

  • taspoglutideDrug

    10mg once weekly for 4 weeks followed by 20mg once weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1cTime frame: 24 weeks

Locations

216 sites in 26 countries. Site status is shown where the registry gives one.

  • Site not named

    Haleyville, Alabama

  • Site not named

    Mobile, Alabama

  • Site not named

    Montgomery, Alabama

  • Site not named

    Tuscaloosa, Alabama

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Escondido, California

  • Site not named

    La Jolla, California

  • Site not named

    Mission Viejo, California

  • Site not named

    Orange, California

  • Site not named

    Palm Springs, California

  • Site not named

    Rancho Cucamonga, California

  • Site not named

    Sacramento, California

  • Site not named

    San Leandro, California

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    Daytona Beach, Florida

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Green Cove Springs, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami Beach, Florida

  • Site not named

    Niceville, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Atlanta, Georgia

  • Site not named

    Suwanee, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Chicago, Illinois

  • Site not named

    Lombard, Illinois

  • Site not named

    Peoria, Illinois

  • Site not named

    Evansville, Indiana

  • Site not named

    New Albany, Indiana

  • Site not named

    Iowa City, Iowa

  • Site not named

    Munfordville, Kentucky

  • Site not named

    Metairie, Louisiana

  • Site not named

    Bangor, Maine

  • Site not named

    Baltimore, Maryland

  • Site not named

    Bethesda, Maryland

  • Site not named

    Rockville, Maryland

  • Site not named

    Royal Oak, Michigan

  • Site not named

    Jefferson City, Missouri

  • Site not named

    Kansas City, Missouri

Showing 40 of 216 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.